A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Year: 2023
Type: article
Study design: Clinical Trial
Source: European Urology Oncology
Authors: Pavlos Msaouel, Randy F. Sweis, Manojkumar Bupathi, Elisabeth Heath, Oscar B. Goodman, Christopher J. Hoimes, Matthew I. Milowsky, Nancy Davis, Arash Rezazadeh Kalebasty, Joel Picus, David Shaffer, Shifeng Mao, Nabil Adra, Jeffrey Yorio, Sunil Gandhi, Petros Grivas, Arlene Siefker-Radtke, Rui Yang, Lisa Latven, Peter Olson, Curtis D. Chin, Hirak Der-Torossian, Amir Mortazavi, Gopa Iyer
Institutions: The University of Texas MD Anderson Cancer Center, University of Chicago, Rocky Mountain Cancer Centers, The Barbara Ann Karmanos Cancer Institute, Comprehensive Cancer Centers of Nevada, Duke University Hospital, UNC Lineberger Comprehensive Cancer Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, University of California, Irvine, Washington University in St. Louis, New York Oncology Hematology, Albany Medical Center Hospital, Allegheny General Hospital, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Texas Oncology, Florida Cancer Specialists & Research Institute, University of Washington, Fred Hutch Cancer Center, Mirati Therapeutics (United States), The Ohio State University, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4389834006